Nuvation Bio Inc.
corporate_fare Company Profile
Nuvation Bio Inc. (NYSE:NUVB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for NUVB at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Nuvation Bio Secures Major Licensing Deal with Eisai for Taletrectinib, Reports Strong IBTROZI Launch & Path to Profitability
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$62.9M
Net Income
-$204.63M
Diluted EPS
-$0.60
Op. Cash Flow
-$173.43M
Free Cash Flow
-$181.43M
Operating Income
-$213.06M
Cash & Equivalents
$164.09M
Total Debt
$5.72M
Debt / Equity
0.02×
Net Margin
-325.3%
Shares Outstanding
337.84M sh
Source: 10-K · filed 2026-03-02 · accession 0001193125-26-085584
show_chartPrice Chart
Loading chart...
feed NUVB - Filings & News (Page 2)
NUVB
Jan 12, 2026, 8:07 AM EST
Price at Filing:
$7.89
Real-time Price:
$3.80
Change:
-$4.09 (-52%)
Market Cap:
$1.345B